
A study of 98,600 people strengthens the case for using pharmacogenomics when treatment decisions may benefit from it. It does not, however, establish that every patient should receive a genetic test. The key distinction is that common genetic variants linked to medication response are not the same as evidence that population-wide testing improves treatment outcomes.
Researchers at the University of Pittsburgh analysed variants in 16 genes alongside participants’ prescription records. Nauka w Polsce reported that every participant had at least one variant that could affect how medicines work, while nearly a quarter had been prescribed at least one medicine whose effectiveness or safety could depend on their genes. The commonly prescribed medicines cited included ibuprofen, omeprazole, pantoprazole, atorvastatin and ondansetron.
That is a meaningful finding for clinical practice, particularly where genetic guidance is already relevant to a drug choice and for patients taking several medicines. A result could prompt a clinician to consider a different dose, another medicine or closer monitoring. But it should not be treated as an automatic verdict on a treatment. A genetic variant alone does not determine that a medicine will fail or cause adverse effects; medication response has other influences as well.
The researchers suggest a broader one-time test whose results would remain in a medical record and could trigger an alert during prescribing. That is a proposal worth evaluating, not a ready-made policy for everyone. The researchers themselves said wider implementation requires assessment of costs and real-world benefits. The supplied report gives no evidence on the cost-effectiveness of such a programme, reimbursement rules in Poland or whether the study population represents Polish patients.
The useful conclusion is therefore more disciplined than a promise of medicines tailored to everyone: pharmacogenomics merits broader assessment where it can change a clinical decision, but the prevalence of relevant variants cannot substitute for evidence that testing every patient improves care.
Sources
- Nauka w Polsce · Fundacja PAP — Źródło: Nauka w Polsce (Fundacja PAP) (https://naukawpolsce.pl/) · Source date: 2026-11-17
Independent editorial content. WUA is not affiliated with any political party. 2026-11-17